Improved Engraftment of Hematopoietic Stem Cells
An improved method of obtaining hematopoietic stem cells (HSCs) has been developed. The stem cells have increased engraftment potential, and can be used in the treatment of blood-based cancers, such as leukemia. The technology uses the Tissue Factor Pathway Inhibitor (TFPI) to inactivate CD26 activity and improve homing to the chemokine stroma-derived factor 1-alpha present in the bone marrow “niche”. This increases the engraftment potential of HSCs and allows for better use in grafts with limited numbers of HSCs. The technology provides better treatment outcomes in patients with blood cancers.
Hematopoietic Stem Cell Importance
Hematopoietic stem cells, the cells that give rise to all other blood cells, are formed through a process known as hematopoiesis which is necessary for sustaining human life. The cells self-renew to maintain and expand the stem cell pool, but they must differentiate to form committed hematopoietic progenitor cells that progressively lose self-renewal potential and become increasingly restricted in their lineage potential. The processes by which the stem cells differentiate to form the necessary elements to form various blood cells versus self-renewal are poorly understood currently. However, due to the insufficient numbers of hematopoietic stem cells available for research, it is difficult to run tests on the cells to provide more information on their differentiation processes. There is a need for methods that improve the efficacy with which transplanted cells reconstitute the hematopoietic system due to the demand for the hematopoietic stem cells in therapy for diseases and disorders.
BENEFITS AND FEATURES OF IMPROVED ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS:
- Improved engraftment potential for treatment of diseases like leukemia
- Efficiently uses cell stock to improve implant efficacy of stem cells from limited sources
Phase of Development Proof of Concept